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The response evaluation criteria in patients with Hodgkin lymphoma (HL) were designed for the assessment of chemotherapy and targeted molecular agents. We investigated the accuracy of 3-mo 18 F-FDG PET/CT for the identification of HL patients responding to immune-checkpoint blockade by anti-programmed death 1 antibodies (anti-PD1). We also reported the frequency of new immune patterns of response and progression. Methods: Retrospectively, we recruited consecutive HL patients treated by anti-PD1 (pembrolizumab or nivolumab) at Gustave Roussy from 2013 to 2015. 18 F-FDG PET/CT and contrast-enhanced CT scans were acquired every 3 mo. We recorded the best overall response according to the International Harmonization Project Cheson 2014 criteria and LYmphoma Response to Immunomodulatory therapy Criteria (LYRIC) (2016 revised criteria). Patients achieving an objective response at any time during the anti-PD1 treatment were classified as responders. Results: Sixteen relapsed or refractory classic HL patients were included. The median age was 39 y (age range, 19-69 y). The median previous lines of therapy was 6 (range, [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] . The mean follow-up was 22.6 mo. Nine of 16 patients (56%) achieved an objective response. Two deaths occurred due to progressive disease at 7 mo. 18 F-FDG PET/CT detected all responders at 3 mo and reclassified best overall response in 5 patients compared with CT alone. A decrease in tumor metabolism and volume (SUV mean , metabolic tumor volume) and increase in healthy splenic metabolism at 3 mo were observed in responders (area under the curve . 0.85, P , 0.04). Five of 16 patients (31%) displayed new imaging patterns related to anti-PD1; we observed 2 transient progressions consistent with indeterminate response according to the LYRIC (2016) (IR2b at 14 mo and IR3 at 18 mo) and 3 patients with new lesions associated with immune-related adverse events. Conclusion: Three-month 18 F-FDG PET/CT scans detected HL patients responding to anti-PD1. New patterns were encountered in 31% of patients, emphasizing the need for further evaluation in larger series and close collaboration between imaging and oncology specialists on a per-patient basis. Hodgki n Reed-Sternberg cells escape immune surveillance through a genetic alteration in chromosome 9p24.1, leading to an overexpression of the programmed death 1 (PD1) ligands (1) . Pembrolizumab and nivolumab are PD1 blockade antibodies (anti-PD1) that restore immunity against Hodgkin Reed-Sternberg cells. Anti-PD1 has recently demonstrated high (64%-87%) response rates in relapsed or refractory Hodgkin lymphoma (HL) (2, 3) .
Hodgkin lesions constitute a unique microenvironment, with a minority of Hodgkin Reed-Sternberg cells (often ,1%) that interact with numerous microenvironment cells (4) (5) (6) . The high avidity of Hodgkin lesions for glucose analog translates into a high 18 F-FDG uptake visible on PET (7) . The Warburg effect (8) leads to an important increase in glucose consumption in proliferative tissue or tumor (as compared with differentiated tissue) due to an increase in anaerobic glycolysis. Theoretically, anti-PD1 could lead to an activation of antitumor microenvironment immune cells, translating into increased glucose metabolic consumption by an upregulation of Glut messenger RNA (to provide cellular energy), and upregulation of Glut proteins (to compete for hexoses uptake) (9,10), leading to increased 18 F-FDG uptake (11) . This could mask anti-PD1 treatment efficacy on 18 F-FDG PET in HL.
Anti-PD1 induces new patterns of progression and possibly new response paradigms that can alter decision making in patients' management and ultimately patient outcomes. Indeed, 5%-10% of patients with solid tumors (12) experience pseudoprogression, usually early during treatment, with imaging findings suggestive of progressive disease but followed by later imaging response (12) (13) (14) (15) (16) (17) . In 2016, the LYmphoma Response to Immunomodulatory therapy Criteria (LYRIC) introduced the term indeterminate response (IR)-instead of progression-as the time interval until a biopsy or subsequent imaging confirmed either a pseudoprogression or a true progression (18) , restraining clinicians to a wait-and-see strategy. Additionally, new immune patterns were described such as abscopal effect (i.e., a tumor's antigens released by radiotherapy lead to the regression of metastatic cancer size and metabolism at a distance from the irradiated site due to the enhancement of the diversity of the T-cell receptor) (19) and hyperprogression (i.e., anti-PD1 initiation leads to a paradoxal increase in tumor growth rate) (20) .
The reference standards for the monitoring of HL are CT scanning and 18 F-FDG PET (18, 21, 22) . Interim 18 F-FDG PET is indeed crucial for assessing the response to adriamycin, bleomycin, vinblastine, and dacarbazine (23) as well as bleomycin, etoposide, adriamycin, cyclophosphamide, oncovin, procarbazine, and prednisone regimen (24) . The current response criteria were, however, designed for chemotherapies and drugs targeting the cancer cells. Therefore, a treatment response is defined by a tumor shrinkage (IWG-Cheson) (22) or a decrease of tumor glycolytic metabolism (Lugano classification) (21) within Hodgkin lesions. Imaging-based response evaluation criteria should now integrate the paradigm shift introduced by anti-PD1, which aims the activation of the antitumor immune system. We investigated, in a pilot patient-based and lesion-based imaging study, the metabolic pattern of response in HL treated with anti-PD1.
MATERIALS AND METHODS

Patient Selection
Patient selection and treatment are presented in Table 1 . In a singlecenter study, 16 adult HL patients treated with anti-PD1 were retrospectively selected, 15 treated by pembrolizumab intravenously in clinical trials (NCT01953692, NCT02453594) and 1 treated by nivolumab intravenously in a compassionate program. Patients were treated for HL relapsing or refractory to salvage chemotherapy including brentuximab vedotin and autologous stem cell transplantation at Gustave Roussy, from December 2013 to December 2015. All patients underwent 18 F-FDG PET and contrast-enhanced CT evaluations at baseline and every 3 mo until progression or cessation of treatment for up to 2 y. The protocols (NCT01953692 and NCT02453594) were approved by ethics committee, and all subjects signed a written informed consent form. 
F-FDG PET and CT Scan Acquisitions
Response Evaluation Criteria
A central consensus review of all imaging data was performed. The change in the sum of the product of the perpendicular diameters of target lesions (DSPD-Cheson) on contrast-enhanced CT scans was measured using Cheson 2014 criteria (18, 21, 22) . The evolution of nontarget lesions and new lesions was recorded. The 18 F-FDG PET scan was scored according to the 5-point scale scoring system (PET-5PS) (18, 21, 22) : no uptake; uptake , mediastinum; uptake . mediastinum but , liver; uptake moderately more than liver uptake, at any site; and markedly increased uptake at any site or new sites of disease.
Monitoring of Imaging Studies
The changes in CT and PET biomarkers across the anti-PD1 treatment sequence was measured ( Table 2) to compute their predictive value (Table 3) : skeletal muscle index on CT scans (marker of sarcopenia, predictor of outcome (26)); metabolic tumor volume (MTV) and total lesion glycolysis (TLG) measured inside the whole tumor volume defined by Lugano criteria (18, 21, 22) using the Nestle approach for the segmentation (27) ; SUV max and SUV mean measured inside the whole tumor volume previously segmented; and glucose consumption of healthy lymphoid tissue (spleen, thymus, ileocaecal valve, and healthy osteomedullary bone) (our driving hypothesis was that the activation of antitumor immunity by anti-PD1 could translate into increased glucose consumption outside the Hodgkin tumor lesions).
Monitoring of Nonimaging Biomarkers
The variation in full blood count parameters across the treatment sequence was measured ( Table 4 ).
Pattern of Response and Progression
Best overall response (BOR) was defined per Cheson 2014 criteria (2) and took into consideration the 2016 LYRIC classification concept of IR (18) ( Table 5 ). Patients having achieved an objective partial or complete response at any time during the treatment were defined as responders. Patients having achieved stability or progression as BOR at any time were classified as refractory. The reference standard was the multidisciplinary experts' consensus based on clinical and imaging results and if feasible on biopsy and histology when an 18 F-FDGpositive lesion was persistent (18, 21, 22) .
Identification of Responders to Anti-PD1 at 3 Months
For all patients, we measured the change in response evaluation criteria, imaging biomarkers, and full blood count parameters between baseline and 3 mo (Tables 2 and 3 ). We evaluated whether 3-mo changes in biomarkers allowed for the identification of patients responding to anti-PD1 (Tables 2 and 3 ).
Lesion-Based Analysis
In a subset of 290 Hodgkin lesions identified at baseline, we monitored the glucose consumption at 3, 6, and 9 mo and calculated the positive and negative predictive value (PPV and NPV) of the PET-5PS (Table 6 ).
Statistical Methods
Descriptive statistics were performed using conventional metrics (mean, median, range). Nonparametric tests were used for comparison or correlation. Wilcoxon tests compared the mean value of the 2 populations. The area under the receiver-operating-characteristic curve (AUC) evaluated the accuracy of imaging features for the detection of refractory patients. Statistical analyses were performed using SPSS software (version 23.0; IBM).
RESULTS
Patients' Characteristics
Patients' Characteristics ( Table 1 ). The anti-PD1 median period between lymphoma diagnosis and initiating anti-PD1 treatment was 4.4 y (range, 0.6-14.8). Patients had a median of 6 (range, 3-13) previous therapeutic lines. Sixteen patients received previous chemotherapy, and 8 patients received autologous stem cell transplantation. Data are distribution of imaging biomarkers in refractory and responding patients at baseline (BL) and changes 3 mo after anti-PD1 initiation (D3, expressed as a percentage). Wilcoxon test showed significant differences between the 2 groups.
Treatment. Nine of 16 patients achieved an objective response. Thirteen patients stopped treatment after a mean duration of 15.3 mo at the cutoff date of analysis. The mean follow-up was 22.6 mo. The estimated (95% confidence interval) overall survival in the overall population was 34.7 mo (29.6-39.7 mo) according to Kaplan-Meier analysis. None of the patients with a negative 18 F-FDG PET result died. Two patients died because of progressive disease at 7 mo (patients 7 and 9).
Change in Anthropomorphic Characteristics. At 3 mo, there was no significant difference between responders and refractory patients. At 6 mo and beyond, stability or improvement of the skeletal muscle index was observed in 10 of 16 patients, mostly in the responders (Figs. 1-3 ). Data are distribution of biologic biomarkers in refractory and responding patients at baseline (BL) and change 3 mo after anti-PD1 initiation (D3, expressed as a percentage). Wilcoxon test did not show significant mean differences between those 2 groups. Responders had significant decrease in tumor volume and metabolism and increase in spleen metabolism at 3 mo. Data in parentheses are 95% confidence intervals. PET/CT score 4 or 5 with reduced uptake compared with baseline and residual masses of any size. OR On CT $50% decrease in SPD of up to 6 target measurable nodes and extranodal sites.
Patterns of Response and Progression in Patients
PET/CT score 4 or 5 with an increase in intensity of uptake from baseline or new 18 F-FDG-avid foci consistent with lymphoma at interim or end-oftreatment assessment. OR On CT, an individual node/lesion must be abnormal with: LDi . 1.5 cm and increase by $50% from product of the perpendicular diameters nadir and an increase in LDi or SDi from nadir 0.5 cm for lesions # 2 cm and 1.0 cm for lesions . 2 cm.
In the setting of splenomegaly, the splenic length must increase by .50% of the extent of its prior increase beyond baseline (e.g., a 15cm spleen must increase to .16 cm). If no prior splenomegaly, must increase by $2 cm from baseline. New or recurrent splenomegaly.
New or clear progression of preexisiting nonmeasured lesions.
Regrowth of previously resolved lesions
A new node . 1.5 cm in any axis or a new extranodal site . 1.0 cm in any axis; if ,1.0 cm in any axis, its presence must be unequivocal and must be attributable to lymphoma.
Assessable disease of any size unequivocally attributable to lymphoma.
AND/OR new or recurrent involvement of the bone marrow.
LYRIC Same as Lugano Same as Lugano
As with Lugano with the following exceptions:
IR1: $50% increase in SPD in first 12 wk.
IR2a: ,50% increase in SPD with new lesions.
IR2b: ,50% increase in SPD with $50% increase in PPD of a lesion or set of lesions at any time during treatment.
IR3: Increase in 18 F-FDG uptake without a concomitant increase in lesion size meeting criteria for progressive disease. 6 mo after treatment initiation was widely different among patients ( Figs. 1-3 ).
Depth of Response Over Time. All patients who achieved objective response did it at the first 3-mo assessment. Figure 1 shows that the depth of the response in most patients slightly increased between 3 and 6 mo and even for patients 1, 4, 5, and 6 lasted for more than 1 y.
IRs by LYRIC. Seven patients were indeterminate, 5 proved to be true progressions and 2 transient progressions. Patient 16 had IR1 ($50% increase in SPD in first 12 wk) and IR2 (,50% increase in SPD with new lesions or progression of a lesion) profiles: new lesion and increase in tumor burden at 3 mo without clinical deterioration that were subsequently confirmed as tumor lesions. Six of sixteen patients analyzed during the first 6 mo were qualified as IR2a (a new lesion at any time). In these 6 patients, 46 new tumors sites were detected (lesion sites: 30 lymph node, 7 lung, 6 spleen, 2 bone, and 1 multifocal bone involvement). All these new lesions persisted and were considered as progressive lesions. Patient 4 experienced an IR2b between 14 and 16 mo ( Fig. 4) : transient progression in tumor size and 18 F-FDG uptake. In patient 1 (Fig. 5) , a transient progression of SUV max is detailed; the lesion qualified as IR3 but ultimately progressed morphologically and metabolically at 36 mo after the discontinuation of anti-PD1. New Nontumor Lesions. Six patients had new 18 F-FDG-positive lesions during anti-PD1 treatment (Fig. 6 ) that were not tumor lesions. 18 F-FDG PET detected concurrent pulmonary infection and zona activation in patients 5 and 14. 18 F-FDG PET detected immune-related adverse events (IRAEs) in patients 3, 6, 9, and 16: 1 confirmed colitis, 2 interstitial pneumonitis (1 confirmed as IRAE), and 1 confirmed pancreatitis.
Hyperprogression. There was no case of hyperprogression. The tumor growth rate decreased in all patients after anti-PD1 initiation (e.g., Fig. 7 ).
3-Month Prediction of BOR
We evaluated whether early changes in CT scans, PET scans, and blood biologic biomarkers measured at baseline and 3 mo predicted BOR and thus identified responders to anti-PD1. The most accurate biomarker was DMTV according to receiver-operating-characteristic analysis (Tables 2 and 3) .
Change in Tumor Burden. The mean shrinkage of target tumor lesions at 3 mo was significantly greater in responders We evaluated glucose metabolism within 290 Hodgkin lesions at baseline and every 3 mo after anti-PD1 initiation. PET-5PS had excellent NPV and PPV. ( Table 2) as demonstrated by DSPD-Cheson, DMTV, and DTLG (P , 0.03). The AUC of those biomarkers was above 0.95 (P , 0.008) ( Table 3) . No refractory patients achieved MTV shrinkage greater than 50% at 3 mo (sensitivity: 71%, specificity: 100%).
PET-5PS. PET-5PS was not significantly different between refractory and responding patients, as demonstrated by the comparison of the mean value (P 5 0.13, Table 2 ) and the AUC (P 5 0.13, Table 3 ).
Change in Tumor Glucose Consumption.
Responders had significantly greater decrease in SUV mean and SUV max , for which the AUC was above 0.87 (P , 0.03) (Tables 2 and 3) . A 3-mo decrease in SUV max (D , 250%) was observed exclusively in responders.
Change in Healthy Lymphoid Tissue SUV max . The variation of glucose consumption within healthy lymphoid tissues was not measurable in some patients because of splenectomy (patient 12), thymus infiltration (patient 13), and osteomedullary infiltration (patient 11). A significant increase in spleen glucose consumption-DSUV max -was observed in responders (Tables 2 and 3 ). Variation in glucose consumption within spleen, thymus, and bone medulla were not statistically significant (P . 0.21) predictors of outcome.
Change in Full Blood Count Parameters. No change in full blood count parameters was significantly associated with immune response ( Table 4 ).
Lesion-Based Analysis
PPV and NPV. Table 6 shows the excellent accuracy of the PET-5PS classification for the prediction of the outcome of a Hodgkin lesion at 3, 6, and 9 mo. The PPV and the NPV were, respectively, above 88% and 97% with no pseudoprogression phenomenon observed.
Correlation Between 18 F-FDG Uptake and Biopsies. Good correlation was shown between persistent 18 F-FDG uptake and persistent tumor Hodgkin Reed-Sternberg cells in 3 biopsies performed in 3 different patients at 24.7 (patient 2), 23.1 (patient 4), and 9.6 mo (patient 12).
DISCUSSION
To the best of our knowledge, this is the first study of new metabolic patterns of response in HL patients treated with anti-PD1 at a patient and lesion level. 18 F-FDG PET allowed for refinement of BOR classification in one third of patients as compared with CT scanning only, demonstrating the potential added value of 18 F-FDG PET for response assessment.
The evaluation of anti-PD1 treatment effect by 18 F-FDG PET at 3 mo is clinically relevant, as it clearly identifies responders. Indeed, all responders have reached the response by 3 mo. Future studies might evaluate the predictive value of earlier evaluation.
On a 18 F-FDG PET interpretation perspective, we showed that the PET-5PS has an excellent positive and predictive value at a lesion level although it might be outperformed by quantitative PET metrics on a patient-based analysis (2) . Indeed, the persistence of 18 F-FDG PET-positive lesions at 3 mo does not preclude a prolonged clinical benefit. Our pilot study described the significant shrinkage in tumor volume (DSPD-Cheson, DMTV, DTLG), decrease in tumor glucose metabolism (DSUV mean , DSUV max ), and increase in spleen metabolism observed in responders (n 5 9), which may be useful for the calibration of decision support classification threshold. Additionally, we showed that the interpretation of SUV max needs to be made carefully because transient progression of SUV max can be observed in lesions (Figs. 4 and 5) , and the association between SUV max variation and treatment response is not obvious. Interestingly, healthy spleen tissue 18 F-FDG uptake appears significantly increased in responders, suggesting a favorable immunologic reconstitution. Further prospective and largest studies are required to validate these biomarkers.
Most patients have achieved a good partial and prolonged response, whereas only a few patients were in a complete response. We have confirmed, through histologic restaging, that residual 18 F-FDG-positive lesions remained of lymphomatous origin. As described by Armand et al. (2) and the redefined LYRIC 2016 classification (18) , we observed in the present series 13% of IRs. Importantly, we did not find any early pseudoprogression as defined at 3 mo, as all the new lesions observed at that time had proved to be real progressions. The IRs observed in our series were delayed. These IRs occurred beyond the first year of treatment, with transient fluctuations in tumor size or glucose uptake of residual Hodgkin lesions. In a daily management point of view, the IRs are important to be considered if the patient is clinically doing well, encouraging physicians to not prematurely withdraw the patient from anti-PD1 treatment. Otherwise, 18 F-FDG PET had detected nontumor lesions in 37% of patients, mainly related to immune side effects. In contrast to solid tumors studies, we have not encountered hyperprogression profiles (20) in this pilot series.
CONCLUSION
These data demonstrate that the 18 F-FDG PET evaluation of anti-PD1 treatment is different from classic chemotherapy. Patients may remain in prolonged partial responses, while continuing to likely benefit from anti-PD1 treatment. New imaging patterns related to anti-PD1 were encountered in 31% of patients. 18 F-FDG PET may also reveal IRs mainly during the second year of treatment, as well as nontumor lesions mainly due to immune-related adverse events. 
